FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097617059> ?p ?o ?g. }

• W2097617059 endingPage "2309" @default.
• W2097617059 startingPage "2304" @default.
• W2097617059 abstract "We conducted a randomized phase II study to evaluate the impact of adding bevacizumab (B) to 5-fluorouracil (5-FU), hydroxyurea (HU), and radiotherapy (FHX) for intermediate-stage and select T4 head and neck squamous cell cancers (HNSCC).Eligible patients had newly diagnosed HNSCC. Randomization was 2:1 in favor of BFHX. All patients received 500 mg HU p.o. b.i.d., 600 mg/m(2)/day continuous infusion 5-FU, and b.i.d. radiotherapy with or without bevacizumab 10 mg/kg administered on day 1 of each 14-day cycle. Patients received five cycles consisting of chemoradiotherapy for 5 days followed by 9 days without therapy.Twenty-six patients were enrolled (19 BFHX and 7 FHX). The study was halted following unexpected locoregional progression. Two-year survival was 68%; 89% treated with FHX and 58% (95% confidence interval 33% to 78%) treated with BFHX. Two-year locoregional control was 80% after chemoradiotherapy and 85% after surgical salvage. All locoregional progression occurred in T4 tumors randomized to BFHX. Two patients receiving BFHX died during therapy, and one died shortly after therapy. No catastrophic bleeding events were seen.Locoregional progression seen in T4N0-1 tumors treated with BFHX was unexpected and led to study termination. The addition of bevacuzimab to chemoradiotherapy for HNSCC should be limited clinical trials." @default.
• W2097617059 created "2016-06-24" @default.
• W2097617059 creator A5002557162 @default.
• W2097617059 creator A5008467612 @default.
• W2097617059 creator A5038481817 @default.
• W2097617059 creator A5045590297 @default.
• W2097617059 creator A5063712400 @default.
• W2097617059 creator A5063904421 @default.
• W2097617059 creator A5066986846 @default.
• W2097617059 creator A5067324005 @default.
• W2097617059 creator A5070574602 @default.
• W2097617059 creator A5077701955 @default.
• W2097617059 date "2011-10-01" @default.
• W2097617059 modified "2023-10-16" @default.
• W2097617059 title "A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers" @default.
• W2097617059 cites W1658047882 @default.
• W2097617059 cites W1965970019 @default.
• W2097617059 cites W1975729567 @default.
• W2097617059 cites W2085018134 @default.
• W2097617059 cites W2089257078 @default.
• W2097617059 cites W2096560865 @default.
• W2097617059 cites W2101995865 @default.
• W2097617059 cites W2107920037 @default.
• W2097617059 cites W2112329047 @default.
• W2097617059 cites W2124290973 @default.
• W2097617059 cites W2242447589 @default.
• W2097617059 cites W2248780175 @default.
• W2097617059 doi "https://doi.org/10.1093/annonc/mdq736" @default.
• W2097617059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21330337" @default.
• W2097617059 hasPublicationYear "2011" @default.
• W2097617059 type Work @default.
• W2097617059 sameAs 2097617059 @default.
• W2097617059 citedByCount "54" @default.
• W2097617059 countsByYear W20976170592012 @default.
• W2097617059 countsByYear W20976170592013 @default.
• W2097617059 countsByYear W20976170592014 @default.
• W2097617059 countsByYear W20976170592015 @default.
• W2097617059 countsByYear W20976170592016 @default.
• W2097617059 countsByYear W20976170592017 @default.
• W2097617059 countsByYear W20976170592018 @default.
• W2097617059 countsByYear W20976170592019 @default.
• W2097617059 countsByYear W20976170592020 @default.
• W2097617059 countsByYear W20976170592021 @default.
• W2097617059 countsByYear W20976170592022 @default.
• W2097617059 countsByYear W20976170592023 @default.
• W2097617059 crossrefType "journal-article" @default.
• W2097617059 hasAuthorship W2097617059A5002557162 @default.
• W2097617059 hasAuthorship W2097617059A5008467612 @default.
• W2097617059 hasAuthorship W2097617059A5038481817 @default.
• W2097617059 hasAuthorship W2097617059A5045590297 @default.
• W2097617059 hasAuthorship W2097617059A5063712400 @default.
• W2097617059 hasAuthorship W2097617059A5063904421 @default.
• W2097617059 hasAuthorship W2097617059A5066986846 @default.
• W2097617059 hasAuthorship W2097617059A5067324005 @default.
• W2097617059 hasAuthorship W2097617059A5070574602 @default.
• W2097617059 hasAuthorship W2097617059A5077701955 @default.
• W2097617059 hasBestOaLocation W20976170591 @default.
• W2097617059 hasConcept C126322002 @default.
• W2097617059 hasConcept C141071460 @default.
• W2097617059 hasConcept C143998085 @default.
• W2097617059 hasConcept C168563851 @default.
• W2097617059 hasConcept C204243189 @default.
• W2097617059 hasConcept C2776694085 @default.
• W2097617059 hasConcept C2777802072 @default.
• W2097617059 hasConcept C2778424827 @default.
• W2097617059 hasConcept C2780456651 @default.
• W2097617059 hasConcept C31760486 @default.
• W2097617059 hasConcept C509974204 @default.
• W2097617059 hasConcept C71924100 @default.
• W2097617059 hasConcept C90924648 @default.
• W2097617059 hasConceptScore W2097617059C126322002 @default.
• W2097617059 hasConceptScore W2097617059C141071460 @default.
• W2097617059 hasConceptScore W2097617059C143998085 @default.
• W2097617059 hasConceptScore W2097617059C168563851 @default.
• W2097617059 hasConceptScore W2097617059C204243189 @default.
• W2097617059 hasConceptScore W2097617059C2776694085 @default.
• W2097617059 hasConceptScore W2097617059C2777802072 @default.
• W2097617059 hasConceptScore W2097617059C2778424827 @default.
• W2097617059 hasConceptScore W2097617059C2780456651 @default.
• W2097617059 hasConceptScore W2097617059C31760486 @default.
• W2097617059 hasConceptScore W2097617059C509974204 @default.
• W2097617059 hasConceptScore W2097617059C71924100 @default.
• W2097617059 hasConceptScore W2097617059C90924648 @default.
• W2097617059 hasFunder F4320332193 @default.
• W2097617059 hasIssue "10" @default.
• W2097617059 hasLocation W20976170591 @default.
• W2097617059 hasLocation W20976170592 @default.
• W2097617059 hasOpenAccess W2097617059 @default.
• W2097617059 hasPrimaryLocation W20976170591 @default.
• W2097617059 hasRelatedWork W1521529922 @default.
• W2097617059 hasRelatedWork W2097617059 @default.
• W2097617059 hasRelatedWork W2122899706 @default.
• W2097617059 hasRelatedWork W2404042595 @default.
• W2097617059 hasRelatedWork W2418474598 @default.
• W2097617059 hasRelatedWork W4212844545 @default.
• W2097617059 hasRelatedWork W4221044984 @default.
• W2097617059 hasRelatedWork W4231596293 @default.
• W2097617059 hasRelatedWork W4282931604 @default.

• next